Thank you, Mr. Chair.
Thank you to my colleagues for moving the amendment.
Thank you, Mr. Thériault, for your indulgence.
Yes, I think we need a little bit more shape to this. The beauty of the amendment is that, if it's adopted today, we can invite the stakeholders immediately to start sending in their feedback to us in written submission form. As Ms. Rempel Garner said, if we don't do that, we're not going to be able to have any input from any patient groups of any type for at least three weeks. This way it gets action on Mr. Thériault's motion immediately.
I want to be clear. I think it also has the additional benefit of helping the committee once we get those written submissions. I think there's a deadline in Ms. Rempel Garner's motion of November 6. Do I have that correct, that it's the deadline for written submissions?
It will allow us then to select from those submissions if we have many to focus on from representative groups. For instance, I don't think we need to hear from 11 patient groups who are going to tell us about the same issue. Nor do we need to hear from many pharmaceutical companies that have the same testimony. It will allow us to zero in on what the committee wants to focus on in terms of the oral testimony.
I do want to state for the record that I think it's very important that we do provide an opportunity, particularly for patient groups, to appear before committee and give us their views on the changes in person. I know there's frustration with the process so far. I think it needs to be said that there have been a number of opportunities for stakeholders to submit their written submissions to the government on the PMPRB changes over the last several years. I think what patient groups want is a chance to get in front of parliamentarians in a personal-appearance format, and I think that needs to be encouraged. We need to facilitate that.
As a matter of pragmatic scheduling, the way I'm viewing this, and I want to just be clear that I understand this, is that we give everybody until November 6 to get their submissions in. Then the committee will take a look at those submissions and decide as a committee whom we need to hear from, and we will schedule—I think it's up to four meetings in the motion, if I understand correctly—a representative sample of the viewpoints.
That's where I'll conclude. I think it is important to get a representative sample because, again, I will point out that there are patient groups and experts who very much support these changes, and there are those who do not. I think the committee needs to hear the full range. I think that by getting the written submissions, it will give the committee a really good sample from which we can choose to make sure that, when we do have our meetings in person, we will have canvassed a very good representative sample of those different points of view.